SE9801474D0 - Quinoline Derivatives - Google Patents

Quinoline Derivatives

Info

Publication number
SE9801474D0
SE9801474D0 SE9801474A SE9801474A SE9801474D0 SE 9801474 D0 SE9801474 D0 SE 9801474D0 SE 9801474 A SE9801474 A SE 9801474A SE 9801474 A SE9801474 A SE 9801474A SE 9801474 D0 SE9801474 D0 SE 9801474D0
Authority
SE
Sweden
Prior art keywords
propyl
iso
butyl
formula
ethyl
Prior art date
Application number
SE9801474A
Other languages
English (en)
Swedish (sv)
Inventor
Anders Bjoerk
Stig Joensson
Tomas Fex
Gunnar Hedlund
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to SE9801474A priority Critical patent/SE9801474D0/xx
Publication of SE9801474D0 publication Critical patent/SE9801474D0/xx
Priority to US09/296,519 priority patent/US6077851A/en
Priority to PT99947036T priority patent/PT1073639E/pt
Priority to BRPI9909925-0A priority patent/BR9909925B1/pt
Priority to YUP-612/00A priority patent/RS50029B/sr
Priority to UA2000085078A priority patent/UA60354C2/uk
Priority to HU0102084A priority patent/HU227709B1/hu
Priority to DE69904162T priority patent/DE69904162T2/de
Priority to CZ20003849A priority patent/CZ297439B6/cs
Priority to APAP/P/2000/001933A priority patent/AP1293A/en
Priority to CN99805581A priority patent/CN1113057C/zh
Priority to IDW20002183A priority patent/ID26277A/id
Priority to EEP200000613A priority patent/EE04275B1/xx
Priority to NZ506641A priority patent/NZ506641A/en
Priority to OA1200000301A priority patent/OA11547A/en
Priority to PCT/SE1999/000676 priority patent/WO1999055678A1/en
Priority to CA002329788A priority patent/CA2329788C/en
Priority to AU43013/99A priority patent/AU747550B2/en
Priority to MEP-2000-612A priority patent/ME00870B/me
Priority to DK99947036T priority patent/DK1073639T3/da
Priority to IL13816099A priority patent/IL138160A0/xx
Priority to TR2000/03061T priority patent/TR200003061T2/xx
Priority to EP99947036A priority patent/EP1073639B1/en
Priority to KR1020007011944A priority patent/KR100571534B1/ko
Priority to ES99947036T priority patent/ES2188242T3/es
Priority to AT99947036T priority patent/ATE228505T1/de
Priority to JP2000545838A priority patent/JP4045069B2/ja
Priority to RU2000129672/04A priority patent/RU2197481C2/ru
Priority to PL99343420A priority patent/PL190441B1/pl
Priority to IL138160A priority patent/IL138160A/en
Priority to IS5615A priority patent/IS2082B/is
Priority to ZA200004601A priority patent/ZA200004601B/en
Priority to NO20005254A priority patent/NO315606B1/no
Priority to HR20000726A priority patent/HRP20000726B1/xx
Priority to HK01105489A priority patent/HK1036618A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE9801474A 1998-04-27 1998-04-27 Quinoline Derivatives SE9801474D0 (sv)

Priority Applications (35)

Application Number Priority Date Filing Date Title
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives
US09/296,519 US6077851A (en) 1998-04-27 1999-04-22 Quinoline derivatives
PL99343420A PL190441B1 (pl) 1998-04-27 1999-04-26 Nowe pochodne 1-metylo-2-okso-chinolino-3-karboksyamidu zawierające je kompozycje farmaceutyczne oraz sposób ich wytwarzania
CA002329788A CA2329788C (en) 1998-04-27 1999-04-26 Quinoline derivatives
DK99947036T DK1073639T3 (da) 1998-04-27 1999-04-26 Chinolinderivater
YUP-612/00A RS50029B (sr) 1998-04-27 1999-04-26 Derivati hinolina
UA2000085078A UA60354C2 (uk) 1998-04-27 1999-04-26 Похідні хіноліну, спосіб їх одержання (варіанти) та спосіб лікування ссавців
HU0102084A HU227709B1 (en) 1998-04-27 1999-04-26 Quinoline derivatives, process for producing them and pharmaceutical compositions containing them
DE69904162T DE69904162T2 (de) 1998-04-27 1999-04-26 Chinolinderivate
CZ20003849A CZ297439B6 (cs) 1998-04-27 1999-04-26 Deriváty chinolinu
APAP/P/2000/001933A AP1293A (en) 1998-04-27 1999-04-26 Quinoline derivatives.
CN99805581A CN1113057C (zh) 1998-04-27 1999-04-26 喹啉衍生物
IDW20002183A ID26277A (id) 1998-04-27 1999-04-26 Turunan-turunan kuinolina
EEP200000613A EE04275B1 (et) 1998-04-27 1999-04-26 Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
NZ506641A NZ506641A (en) 1998-04-27 1999-04-26 Quinoline derivatives useful in the treatment of autoimmune disorders
OA1200000301A OA11547A (en) 1998-04-27 1999-04-26 Quinoline derivatives.
PCT/SE1999/000676 WO1999055678A1 (en) 1998-04-27 1999-04-26 Quinoline derivatives
PT99947036T PT1073639E (pt) 1998-04-27 1999-04-26 Derivados de quinolina
AU43013/99A AU747550B2 (en) 1998-04-27 1999-04-26 Quinoline derivatives
MEP-2000-612A ME00870B (me) 1998-04-27 1999-04-26 Derivati hinolina
BRPI9909925-0A BR9909925B1 (pt) 1998-04-27 1999-04-26 derivados de quinolina, composições farmacêuticas, e, processo para a fabricação de derivados de quinolina.
IL13816099A IL138160A0 (en) 1998-04-27 1999-04-26 Quinoline derivatives
TR2000/03061T TR200003061T2 (tr) 1998-04-27 1999-04-26 Kinolin türevleri
EP99947036A EP1073639B1 (en) 1998-04-27 1999-04-26 Quinoline derivatives
KR1020007011944A KR100571534B1 (ko) 1998-04-27 1999-04-26 퀴놀린 유도체
ES99947036T ES2188242T3 (es) 1998-04-27 1999-04-26 Derivados de quinolina.
AT99947036T ATE228505T1 (de) 1998-04-27 1999-04-26 Chinolinderivate
JP2000545838A JP4045069B2 (ja) 1998-04-27 1999-04-26 キノリン誘導体
RU2000129672/04A RU2197481C2 (ru) 1998-04-27 1999-04-26 Производные хинолина
IL138160A IL138160A (en) 1998-04-27 2000-08-30 Quinoline derivatives
IS5615A IS2082B (is) 1998-04-27 2000-08-31 Kvínólínafleiður
ZA200004601A ZA200004601B (en) 1998-04-27 2000-09-01 Quinoline derivatives.
NO20005254A NO315606B1 (no) 1998-04-27 2000-10-19 Kinolinderivater
HR20000726A HRP20000726B1 (en) 1998-04-27 2000-10-26 Quinoline derivatives
HK01105489A HK1036618A1 (en) 1998-04-27 2001-08-07 Quinoline derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives

Publications (1)

Publication Number Publication Date
SE9801474D0 true SE9801474D0 (sv) 1998-04-27

Family

ID=20411103

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9801474A SE9801474D0 (sv) 1998-04-27 1998-04-27 Quinoline Derivatives

Country Status (33)

Country Link
EP (1) EP1073639B1 (sh)
JP (1) JP4045069B2 (sh)
KR (1) KR100571534B1 (sh)
CN (1) CN1113057C (sh)
AP (1) AP1293A (sh)
AT (1) ATE228505T1 (sh)
AU (1) AU747550B2 (sh)
BR (1) BR9909925B1 (sh)
CA (1) CA2329788C (sh)
CZ (1) CZ297439B6 (sh)
DE (1) DE69904162T2 (sh)
DK (1) DK1073639T3 (sh)
EE (1) EE04275B1 (sh)
ES (1) ES2188242T3 (sh)
HK (1) HK1036618A1 (sh)
HR (1) HRP20000726B1 (sh)
HU (1) HU227709B1 (sh)
ID (1) ID26277A (sh)
IL (2) IL138160A0 (sh)
IS (1) IS2082B (sh)
ME (1) ME00870B (sh)
NO (1) NO315606B1 (sh)
NZ (1) NZ506641A (sh)
OA (1) OA11547A (sh)
PL (1) PL190441B1 (sh)
PT (1) PT1073639E (sh)
RS (1) RS50029B (sh)
RU (1) RU2197481C2 (sh)
SE (1) SE9801474D0 (sh)
TR (1) TR200003061T2 (sh)
UA (1) UA60354C2 (sh)
WO (1) WO1999055678A1 (sh)
ZA (1) ZA200004601B (sh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
KR100908655B1 (ko) 2002-11-27 2009-07-21 엘지디스플레이 주식회사 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
MX2007007599A (es) 2004-12-21 2007-12-07 Serono Lab Dervivados ciclicos de sulfonilamino y uso de los mismos.
UA86862C2 (en) 2005-01-31 2009-05-25 Лаборатуар Сероно С.А. N-hydroxyamide derivatives and use thereof
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
US8178083B2 (en) 2005-09-01 2012-05-15 Ares Trading, S.A. Treatment of optic neuritis
JP5832716B2 (ja) 2005-10-19 2015-12-16 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶，及びその製造方法
SI2035001T1 (sl) 2006-06-12 2012-03-30 Teva Pharma Stabilni pripravki lakvinimoda
PL2682120T3 (pl) 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stabilne preparaty lakwinimodu
NZ591315A (en) * 2008-09-03 2012-08-31 Teva Pharma 2-oxo-1,2-dihydro-quinoline modulators of immune function
AU2010276748A1 (en) * 2009-07-30 2012-03-15 Teva Pharmaceutical Industries Ltd. Treatment of Crohn's disease with laquinimod
HUE029983T2 (en) 2009-08-10 2017-04-28 Teva Pharma Treatment of BDNF-related diseases with laquinimod
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
SG183515A1 (en) * 2010-03-03 2012-10-30 Teva Pharma Treatment of lupus arthritis using laquinimod
CN102781240A (zh) * 2010-03-03 2012-11-14 泰华制药工业有限公司 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎
WO2011116091A1 (en) 2010-03-17 2011-09-22 Novartis Ag Dispenser
PL2590949T3 (pl) 2010-07-09 2016-06-30 Active Biotech Ab Sposób wytwarzania chinolino-3-karboksyamidów
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP3056205A1 (en) * 2010-07-09 2016-08-17 Teva Pharmaceutical Industries, Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
MX2014004420A (es) 2011-10-12 2014-07-09 Teva Pharma Tratamiento de esclerosis multiple con combinacion de laquinimod y fingolimod.
EA201491460A1 (ru) * 2012-02-03 2015-01-30 Тева Фармасьютикал Индастриз Лтд. ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
WO2013123419A1 (en) 2012-02-16 2013-08-22 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EP2916915A4 (en) * 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
RU2545056C2 (ru) * 2012-12-10 2015-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты
KR20150119227A (ko) * 2013-02-15 2015-10-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN107108510B (zh) 2014-09-23 2020-10-23 活跃生物技术有限公司 用于治疗多发性骨髓瘤的喹啉甲酰胺
CN107072989B (zh) 2014-11-19 2020-07-03 活跃生物技术有限公司 用于治疗白血病的喹啉甲酰胺
EP3886858B1 (en) 2019-12-19 2022-05-11 Active Biotech AB Compounds for treatment of eye diseases associated with excessive vascularisation
KR20220149579A (ko) 2020-03-03 2022-11-08 액티브 바이오테크 에이비 조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
US20230203003A1 (en) * 2020-05-21 2023-06-29 Stemsynergy Therapeutics, Inc. Notch Inhibitors and Uses Thereof
MX2023000903A (es) 2020-07-23 2023-04-20 Univ Erasmus Med Ct Rotterdam Proteinas s100 como nuevos objetivos terapeuticos en neoplasias mieloproliferativas.
KR20230133317A (ko) 2021-01-18 2023-09-19 액티브 바이오테크 에이비 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염
CN117295492A (zh) 2021-05-25 2023-12-26 活跃生物技术有限公司 多个他喹莫德粒子及其用途
EP4363404A1 (en) 2021-07-02 2024-05-08 Active Biotech AB A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
NZ506641A (en) 2002-03-28
PT1073639E (pt) 2003-04-30
ID26277A (id) 2000-12-14
IL138160A (en) 2006-04-10
WO1999055678A1 (en) 1999-11-04
CZ297439B6 (cs) 2006-12-13
YU61200A (sh) 2003-07-07
NO20005254D0 (no) 2000-10-19
DE69904162T2 (de) 2003-08-21
JP4045069B2 (ja) 2008-02-13
ZA200004601B (en) 2002-02-27
HUP0102084A2 (hu) 2001-11-28
NO315606B1 (no) 2003-09-29
HK1036618A1 (en) 2002-01-11
RS50029B (sr) 2008-11-28
PL343420A1 (en) 2001-08-13
IL138160A0 (en) 2001-10-31
RU2197481C2 (ru) 2003-01-27
ATE228505T1 (de) 2002-12-15
DE69904162D1 (de) 2003-01-09
BR9909925B1 (pt) 2010-09-21
AU4301399A (en) 1999-11-16
AP2000001933A0 (en) 2000-12-31
CN1298393A (zh) 2001-06-06
EE04275B1 (et) 2004-04-15
KR100571534B1 (ko) 2006-04-14
HRP20000726B1 (en) 2009-04-30
AU747550B2 (en) 2002-05-16
IS5615A (is) 2000-08-31
AP1293A (en) 2004-08-30
PL190441B1 (pl) 2005-12-30
OA11547A (en) 2004-05-24
CN1113057C (zh) 2003-07-02
JP2002513006A (ja) 2002-05-08
HU227709B1 (en) 2011-12-28
EP1073639B1 (en) 2002-11-27
UA60354C2 (uk) 2003-10-15
HRP20000726A2 (en) 2001-04-30
HUP0102084A3 (en) 2002-12-28
CZ20003849A3 (cs) 2001-03-14
IS2082B (is) 2006-02-15
EP1073639A1 (en) 2001-02-07
TR200003061T2 (tr) 2001-01-22
ES2188242T3 (es) 2003-06-16
BR9909925A (pt) 2001-01-09
DK1073639T3 (da) 2003-03-24
CA2329788A1 (en) 1999-11-04
NO20005254L (no) 2000-12-27
CA2329788C (en) 2004-11-23
ME00870B (me) 2008-11-28
EE200000613A (et) 2002-04-15

Similar Documents

Publication Publication Date Title
SE9801474D0 (sv) Quinoline Derivatives
SE9802549D0 (sv) Quinoline derivatives
AP1425A (en) Quinoline derivatives.
ATE37179T1 (de) Dihydropyridazinone.
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
EE200100513A (et) Rakkude adhesiooni inhibeerivad põletikuvastased ja immunosupressiivsed ühendid
ATE227293T1 (de) 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
AR002711A1 (es) Un compuesto de 2-carboxindol-3-substituido,un proceso para su preparacion, un nuevo compuesto intermediario para dicho proceso, el uso del compuesto parala fabricacion de un agente terapeutico y una composicion farmaceutica que comprende dicho compuesto.
FI955085A (fi) Uudet diosmetiiniyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
EA200400219A1 (ru) Производные хинолина и их использование в качестве противоопухолевых средств
EA200101050A1 (ru) Замещенные бензолактамные соединения
NO833918L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indolderivater
SE0400440D0 (sv) Novel Cinnamic Amides
SE0401578D0 (sv) Novel compounds
DE60009932D1 (de) 5-aminoalkyl- und 5-aminocarbonylsubstituierte indole
FI834789A0 (fi) Foerfarande foer framstaellning av 1,1-difenylpropanolderivat
SE8405332L (sv) 2h-azeto (2,1-a)-isokinolinderivat, forfarande for deras framstellning och farmaceutiska kompositioner innehallande dem
SE9902147L (sv) Nya föreningar och farmaceutiska kompositioner innehållande desamma
RU92016560A (ru) Замещенные бензоимидазолы, фармацевтическая композиция, способ ингибирования или лечения и способ их получения и применение
FI870098A (fi) Nya pregnanderivat, foerfaranden foer deras framstaellning och farmaceutiska preparat, vilka innehaoller desamma.